instruction
stringlengths
33
156
input
float64
output
stringlengths
120
1.97k
Does Abatacept and Fruquintinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Fruquintinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Fusidic acid interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Fusidic acid can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Galantamine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Galantamine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Gefitinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Gefitinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Gemcitabine interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Gemtuzumab ozogamicin interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Gilteritinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Gilteritinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Glasdegib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Glasdegib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Glatiramer interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Glatiramer, and the severity of the interaction is major.
Does Abatacept and Gliclazide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Gliclazide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Glimepiride interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Glimepiride can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Glipizide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Glipizide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Gliquidone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Gliquidone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Glyburide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Glyburide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Golimumab interact?
null
Concomitant use of abatacept and TNF-α inhibitors, which are both immunosuppressive agents, increases the risk of serious infection with no therapeutic benefit. In short, The risk or severity of infection can be increased when Golimumab is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Guselkumab interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Guselkumab, and the severity of the interaction is major.
Does Abatacept and Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Haloperidol interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Haloperidol can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Halothane interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Halothane can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hepatitis A Vaccine interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hepatitis B Vaccine (Recombinant) interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydrocodone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Hydrocodone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydrocortisone acetate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone acetate can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydrocortisone butyrate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone butyrate can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydrocortisone phosphate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone phosphate can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydrocortisone succinate interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Hydrocortisone succinate, and the severity of the interaction is major.
Does Abatacept and Hydrocortisone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydrocortisone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydromorphone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Hydromorphone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydroxychloroquine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Hydroxychloroquine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydroxyprogesterone caproate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydroxyprogesterone caproate can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Hydroxyurea interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Hydroxyzine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Hydroxyzine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ibritumomab tiuxetan interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Ibrutinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Ibrutinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ibuprofen interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Ibuprofen can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Idarubicin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Idarubicin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Idelalisib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Idelalisib can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Ifosfamide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates with a narrow therapeutic index. In short, The metabolism of Ifosfamide can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Iloperidone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Iloperidone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Imatinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Imatinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Imipramine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Imipramine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Indinavir interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Indinavir can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Indomethacin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Indomethacin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Inebilizumab interact?
null
Inebilizumab has immunosuppressive properties. The combination of inebilizumab with other immunosuppressants may increase the risk of infection. In short, The risk or severity of infection can be increased when Abatacept is combined with Inebilizumab, and the severity of the interaction is minor.
Does Abatacept and Infigratinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Infigratinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Infliximab interact?
null
Concomitant use of abatacept and TNF-α inhibitors, which are both immunosuppressive agents, increases the risk of serious infection with no therapeutic benefit. In short, The risk or severity of infection can be increased when Infliximab is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Interferon alfa-2a interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Interferon alfa-2b interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Interferon alfa-n3 interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Interferon beta-1b interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Interferon gamma-1b interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Iptacopan interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Iptacopan can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Irbesartan interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Irbesartan can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Irinotecan interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Irinotecan can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Isavuconazole interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Isavuconazole can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Isavuconazonium interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Isavuconazonium can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Isoflurane interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Isoflurane can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Istradefylline interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Istradefylline can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ivacaftor interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ivacaftor can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ivosidenib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ivosidenib can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Ixabepilone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ixabepilone can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Ixazomib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Ixazomib can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Ixekizumab interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Ixekizumab, and the severity of the interaction is major.
Does Abatacept and Janssen COVID-19 Vaccine interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ketamine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Ketamine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ketorolac interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Ketorolac can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Labetalol interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Labetalol can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Lacosamide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Lacosamide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Lansoprazole interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Lansoprazole can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Lapatinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Lapatinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Lefamulin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Lefamulin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Leflunomide interact?
null
The immunosuppressive effects of leflunomide may be augmented by the concurrent administration of immunosuppressive agents, leading to an increased risk of serious infection and/or lymphoproliferative disorders resulting from bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Leflunomide, and the severity of the interaction is moderate.
Does Abatacept and Lemborexant interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Lemborexant can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Lenalidomide interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Lercanidipine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Lercanidipine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Letrozole interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Letrozole can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Levamlodipine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Levamlodipine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Levobupivacaine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Levobupivacaine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Levonorgestrel interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Levonorgestrel can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Lidocaine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Lidocaine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Linagliptin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Linagliptin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Linezolid interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Linezolid is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Magnesium interact?
null
Co-administration of magnesium with certain immunosuppressive agents (cyclosporin, ritodrine) may lead to a decrease in serum concentrations of magnesium. In short, The serum concentration of Magnesium can be decreased when it is combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Maprotiline interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Maprotiline can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Mavacamten interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Mavacamten can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Measles virus vaccine live attenuated interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Mechlorethamine interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Meclizine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Meclizine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Mefenamic acid interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Mefenamic acid can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Melatonin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Melatonin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Meloxicam interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Meloxicam can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Melphalan interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Melphalan is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Meperidine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Meperidine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Mepolizumab interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Mepolizumab, and the severity of the interaction is major.
Does Abatacept and Mercaptopurine interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Metamfetamine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Metamfetamine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Methadone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Methadone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Methimazole interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Methimazole is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Methotrexate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Methotrexate can be increased when combined with Abatacept, and the severity of the interaction is major.